
Nvidia's set to regain some China access. But it still faces eroding AI chip market share
The Trump administration last month gave Nvidia assurances that it would be permitted to resume sales of its H20 chips to China, after their exports had been effectively banned in April. It also announced a new "fully compliant" made-for-China chip.
The move was seen as a huge win for the company, which had flagged billions in losses due to the policy. But while the H20s might be returning to the Chinese market that doesn't mean Nvidia will regain its former market share, analysts caution.
In a recent report, global equity research and brokerage firm Bernstein forecast that Nvidia's AI chip market share in China would drop to 54% in 2025, from 66% the year prior.
This drop is only partly owed to complications with resuming chip supply, as Chinese AI chipmakers have been seizing more of the booming domestic market.
"U.S. export controls have created a unique opportunity for domestic AI processor vendors, as they are not competing with the most advanced global alternatives," Bernstein's report said, noting growing prominence of Chinese players such as Huawei, Cambricon and Hygon. "The localization ratio of China's AI chip market will surge from 17% in 2023 to 55% by 2027."
Other analysts such as The Futurum Group CEO Daniel Newman were more bullish about Nvidia's bounce back in China. However, he also flagged potential market share erosion from Nvidia customers that might have found success with Chinese rivals while the H20 controls were in place.
It's also worth noting that Bernstein's predictions assume that broader U.S. chip restrictions will remain largely unchanged. That creates a dynamic where Chinese companies continue to develop and offer advanced chips, possibly eroding demand for outdated U.S. offerings.
Ahead of rolling back the H20 restrictions, Nvidia CEO Jensen Huang had been lobbying for more access to China, claiming export controls were inhibiting U.S. tech leadership.
While Trump administration officials had said the rollback was part of trade negotiations, analysts have echoed Nvidia's basic argument that chip controls for the China market should be eased, thereby creating more dependency on U.S. tech offerings.
"The assumption is that by keeping U.S. technology companies in the China game, the U.S. can preserve and even grow its geopolitical leverage," Reva Goujon, director at Rhodium Group, told CNBC.
In a report last month, Rhodium Group said that this logic may see the administration shift to a "sliding scale" approach to export restrictions that could allow U.S. chipmakers greater access to China as Huawei and other Chinese chipmakers continue to upgrade.
However, while Chinese AI developers will be happy to have increased access to Nvidia chips, Beijing isn't expected to slow its efforts to steer companies toward homegrown AI infrastructure, according to Goujon.
She noted that the Cyberspace Administration of China's recent summons to Nvidia was an obvious signal of the state's intention to intervene in the local AI infrastructure market.
According to the Cyberspace Administration of China, Nvidia met with Beijing officials on Thursday regarding national security concerns posed by the H20 chips, including potential backdoors that would allow parties in the U.S. to access or control them.
Beijing's move appeared to come in response, at least partially, to new laws proposed in the U.S. that would require semiconductor companies such as Nvidia to include security mechanisms and location verification in their advanced AI chips. Nvidia later denied that its chips have any "backdoors" that would allow external access or control.
The move by Beijing was also likely an attempt to create some hesitation among Chinese AI developers looking to buy the new H20s, according to Futurum's Newman.
"China wants to leave some levers in place to potentially restrict outside AI chips at some point down the line if and when it feels its homegrown technology is truly competitive," Newman said.
Beijing has previously restricted American chipmakers' business in China amid periods of intense technology and trade tensions between the two countries. Micron Technology, for instance, failed a cybersecurity review in 2023 and was subsequently blocked from critical IT infrastructure.
"The continued complexity of China-U.S. trade relations could bring further complications [for Nvidia] as negotiations continue and as China attempts to cement its own AI strategy," Newman added.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
25 Stocks to Avoid in August, Historically
Dollar Tree Inc (NASDAQ:DLTR) stock nabbed a record high of $116.51 yesterday after an overdue price-target hike from Bernstein to $109 from $86. However, despite a 54.5% year-to-date gain, the discount retailer is entering a period of historical bearishness. DLTR is one of the worst stocks to own in August, per Schaeffer's Senior Quantitative Analyst Rocky White. Per the table above that goes back 10 years, the equity averages a monthly loss of 8.2%, finishing the month lower 80% of the time over the past 10 years. This makes it the worst performer on the list, which also happens to feature sector peer Dollar General (DG). A comparable move would continue the recent consolidation pattern the shares have formed in the last few weeks. Other factors working against DLTR is the stock's 14-Day Relative Strength Index (RSI), firmly in "overbought" territory at 72. Also note the ascending trendline in the chart below, an area that has alternated between support and resistance since those April bottoms. With earnings not until September 10, options are an intriguing route. The equity's Schaeffer's Volatility Index (VIX) of 27% sits in the bottom percentile of its annual range, meaning options traders are pricing in low volatility expectations. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 minutes ago
- Yahoo
Two Chinese nationals in California accused of illegally shipping Nvidia AI chips to China
By Karen Freifeld (Reuters) -Two Chinese nationals were arrested in California and charged with illegally shipping tens of millions of dollars' worth of AI chips to China, including Nvidia H100s, the U.S. Justice Department said Tuesday. Chuan Geng, 28, of Pasadena, and Shiwei Yang, 28, of El Monte, exported the advanced Nvidia chips and other technology to China from October 2022 through July 2025 without obtaining the required licenses from the U.S. Commerce Department, a criminal complaint says. According to the complaint, Geng and Yang's El Monte-based company, ALX Solutions Inc, was founded in 2022, shortly after the U.S. imposed sweeping export controls on technology to China and began to require licenses for the chips. A spokesperson for Nvidia declined comment. Over 20 shipments from ALX solutions went to shipping and freight forwarding companies in Singapore and Malaysia, which are often used as transshipment points for illegal goods to China. ALX received a $1 million payment from a China-based company in January 2024 and other payments from companies in Hong Kong and China, not the freight forwarding companies. Nvidia H100s are advanced chips that can be used to train large language models and for other applications, such as developing self-driving cars and medical diagnosis systems. Records show that from at least August 2023 to July 2024, ALX Solutions bought over 200 Nvidia H100 chips from San Jose, Calif-based server maker Super Micro Computer, declaring that the end users were in Singapore and Japan. Super Micro did not immediately respond to a request for comment. In addition to Nvidia's H100s, the pair are accused of illegally shipping Nvidia video graphics cards known as PNY GE Force RTX 4090, which also require a license for export to China. Geng and Yang appeared in U.S. District Court in Los Angeles late Monday, according to the Justice Department. Geng, a permanent resident, was released on $250,000 bond. Yang, who overstayed her visa, has a detention hearing on August 12. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 minutes ago
- Yahoo
Pfizer CEO details talks with Trump administration on tariffs, Most Favored Nations pricing
Pfizer (PFE) CEO Albert Bourla said Tuesday he has a "special relationship" with President Trump, cemented during the COVID-19 pandemic when the two were in regular contact to help speed up vaccine production. That relationship, he said, has created a direct line to discuss some of the headwinds the company faces out of Washington, D.C. In his second term, Trump is targeting the drug industry for high prices and overseas production — threatening tariffs as high as 250% on imported drugs. But Bourla told Yahoo Finance he believes Trump and other officials in D.C. are having productive conversations with industry leaders about tariffs and drug pricing. "I think [Trump] is educated, of course he doesn't go into the details, it's not his job, but he understands the dynamics [of the industry]," Bourla said. When asked about the tariff threat, Bourla shared his understanding from his ongoing discussions. "I don't want to speak for the president, but what he said today, which was very important also, was that it would be a very small tariff in the first couple of years. And then he opened the window for a grace period. Because I had this discussion with him and I had this discussion with multiple other members of the administration," Bourla said. Read more: What Trump's tariffs mean for the economy and your wallet The industry is awaiting the results of an investigation by the administration into how those tariffs will be implemented — and Bourla said the devil will be in the details. Currently, more than 90% of prescriptions in the US are from generics, which are often the cheapest drug type. Branded drugs are often the most expensive and are largely produced in the US. But some early components of the manufacturing process, key chemicals known as active pharmaceutical ingredients (APIs), are often made overseas in Europe or Asia. That will be important to understand when the final ruling for the tariffs is made. "We need to understand if the API will dictate the country of origin, or where the final product is made," Bourla said. Pfizer is also one of the companies that received a letter from Trump last week detailing demands to reduce prices for Medicare and Medicaid enrollees to match the lowest price paid by developing nations, known as Most Favored Nations (MFN). The company is currently planning for the implementation of reduced prices, as well as working on how to mitigate negative impacts, Bourla said. "We are still discussing it with the president. ... The devil could be in the details in these stages," he said. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data